Published in Toxicology on June 30, 2010
Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol (2011) 1.64
Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol (2015) 1.06
Addressing human variability in next-generation human health risk assessments of environmental chemicals. Environ Health Perspect (2012) 1.00
Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification. In Silico Pharmacol (2013) 0.99
A mechanistic, model-based approach to safety assessment in clinical development. CPT Pharmacometrics Syst Pharmacol (2012) 0.97
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. Drug Metab Dispos (2015) 0.97
Reconstruction of Exposure to m-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation. J Toxicol (2012) 0.90
Spatio-temporal simulation of first pass drug perfusion in the liver. PLoS Comput Biol (2014) 0.86
Modeling bioavailability to organs protected by biological barriers. In Silico Pharmacol (2013) 0.86
Approaches to integrated monitoring for environmental health impact assessment. Environ Health (2012) 0.84
A physiologically based pharmacokinetic model for capreomycin. Antimicrob Agents Chemother (2011) 0.84
A bayesian perspective on estimation of variability and uncertainty in mechanism-based models. CPT Pharmacometrics Syst Pharmacol (2014) 0.83
A multi-scale modeling framework for individualized, spatiotemporal prediction of drug effects and toxicological risk. Front Pharmacol (2013) 0.82
Representative Sinusoids for Hepatic Four-Scale Pharmacokinetics Simulations. PLoS One (2015) 0.80
Novel in vitro and mathematical models for the prediction of chemical toxicity. Toxicol Res (Camb) (2012) 0.78
Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations. PLoS One (2015) 0.78
A mechanistic modeling framework for predicting metabolic interactions in complex mixtures. Environ Health Perspect (2011) 0.78
Predicting volume of distribution with decision tree-based regression methods using predicted tissue:plasma partition coefficients. J Cheminform (2015) 0.77
Physiologically based pharmacokinetic models: integration of in silico approaches with micro cell culture analogues. Curr Drug Metab (2012) 0.76
Toward the development of an in silico human model for indoor environmental design. Proc Jpn Acad Ser B Phys Biol Sci (2016) 0.75
Bayesian Analysis of a Lipid-Based Physiologically Based Toxicokinetic Model for a Mixture of PCBs in Rats. J Toxicol (2012) 0.75
Advancing human health risk assessment: integrating recent advisory committee recommendations. Crit Rev Toxicol (2013) 0.75
Recommendations for biomonitoring of emergency responders: focus on occupational health investigations and occupational health research. Mil Med (2013) 0.75
Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability. Drug Des Devel Ther (2017) 0.75
Impact of Nonalcoholic Fatty Liver Disease on Toxicokinetics of Tetrachloroethylene in Mice. J Pharmacol Exp Ther (2017) 0.75
Translational learning from clinical studies predicts drug pharmacokinetics across patient populations. NPJ Syst Biol Appl (2017) 0.75
Microtechnology-Based Multi-Organ Models. Bioengineering (Basel) (2017) 0.75
Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol Sci (2011) 2.03
Use of Markov Chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age. Risk Anal (2007) 1.61
Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin Pharmacokinet (2011) 1.55
Genomic signatures and dose-dependent transitions in nasal epithelial responses to inhaled formaldehyde in the rat. Toxicol Sci (2008) 1.51
Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach. Toxicol Sci (2005) 1.35
Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives. Toxicology (2006) 1.34
Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol Sci (2010) 1.30
Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab (2008) 1.22
Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. J Expo Sci Environ Epidemiol (2006) 1.19
Is the relationship between prenatal exposure to PCB-153 and decreased birth weight attributable to pharmacokinetics? Environ Health Perspect (2013) 1.14
Evidence of a "clear and consistent threshold" for bladder and liver cancer in the large ED01 carcinogenicity study. Toxicol Sci (2003) 1.12
Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol Sci (2013) 1.10
Prediction of Voriconazole Non-linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach. Clin Pharmacokinet (2015) 1.09
Prediction of intestinal first-pass drug metabolism. Curr Drug Metab (2007) 1.09
Exposure assessment and risk characterization for perfluorooctanoate in selected consumer articles. Environ Sci Technol (2005) 1.04
Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicol Sci (2010) 1.03
Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform. J Toxicol Environ Health A (2006) 1.03
Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. Toxicol Sci (2013) 1.03
In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn (2012) 1.02
Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages. J Toxicol Environ Health A (2013) 1.00
A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. Toxicol Sci (2007) 1.00
Analysis of manganese tracer kinetics and target tissue dosimetry in monkeys and humans with multi-route physiologically based pharmacokinetic models. Toxicol Sci (2010) 0.99
Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol (2006) 0.99
Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites. Regul Toxicol Pharmacol (2006) 0.98
An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther (2012) 0.98
Application of pharmacokinetic data to the risk assessment of inhaled manganese. Neurotoxicology (2006) 0.98
Temporal concordance between apical and transcriptional points of departure for chemical risk assessment. Toxicol Sci (2013) 0.98
A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. Br J Clin Pharmacol (2012) 0.97
Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol (2011) 0.97
Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. Drug Metab Dispos (2013) 0.96
Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. Regul Toxicol Pharmacol (2008) 0.96
The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. Regul Toxicol Pharmacol (2006) 0.96
Can case study approaches speed implementation of the NRC report: "toxicity testing in the 21st century: a vision and a strategy?". ALTEX (2011) 0.95
Time dependencies in perfluorooctylacids disposition in rat and monkeys: a kinetic analysis. Toxicol Lett (2007) 0.95
Formaldehyde: integrating dosimetry, cytotoxicity, and genomics to understand dose-dependent transitions for an endogenous compound. Toxicol Sci (2010) 0.93
The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. ALTEX (2012) 0.93
Naphthalene metabolism in relation to target tissue anatomy, physiology, cytotoxicity and tumorigenic mechanism of action. Regul Toxicol Pharmacol (2007) 0.93
Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit Rev Toxicol (2012) 0.93
Physiologically based pharmacokinetic modeling of fetal and neonatal manganese exposure in humans: describing manganese homeostasis during development. Toxicol Sci (2011) 0.92
Integrating pathway-based transcriptomic data into quantitative chemical risk assessment: a five chemical case study. Mutat Res (2012) 0.92
Application of physiological computational fluid dynamics models to predict interspecies nasal dosimetry of inhaled acrolein. Inhal Toxicol (2008) 0.91
Assessing the relevance of in vitro measures of phthalate inhibition of steroidogenesis for in vivo response. Toxicol In Vitro (2009) 0.91
Making sense of human biomonitoring data: findings and recommendations of a workshop. J Expo Sci Environ Epidemiol (2007) 0.91
Physiologically based pharmacokinetic modeling of arsenic in the mouse. J Toxicol Environ Health A (2004) 0.90
Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul Toxicol Pharmacol (2003) 0.90
Does age affect gastric emptying time? A model-based meta-analysis of data from premature neonates through to adults. Biopharm Drug Dispos (2015) 0.89
Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul Toxicol Pharmacol (2007) 0.89
Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos (2007) 0.89
Associations of Perfluoroalkyl Substances (PFAS) with Lower Birth Weight: An Evaluation of Potential Confounding by Glomerular Filtration Rate Using a Physiologically Based Pharmacokinetic Model (PBPK). Environ Health Perspect (2015) 0.88
Analysis of genomic dose-response information on arsenic to inform key events in a mode of action for carcinogenicity. Environ Mol Mutagen (2010) 0.88
Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Rev Clin Pharmacol (2013) 0.87
Pharmacokinetic modeling of manganese in the rat IV: Assessing factors that contribute to brain accumulation during inhalation exposure. J Toxicol Environ Health A (2008) 0.87
Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions. Drug Metab Dispos (2013) 0.86
Hormesis and adaptive cellular control systems. Dose Response (2008) 0.86
Genome-wide analysis of DNA methylation and gene expression changes in the mouse lung following subchronic arsenate exposure. Toxicol Sci (2010) 0.86
Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough. Toxicol Sci (2011) 0.85
Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model. Toxicol Sci (2009) 0.85
Perchlorate and radioiodide kinetics across life stages in the human: using PBPK models to predict dosimetry and thyroid inhibition and sensitive subpopulations based on developmental stage. J Toxicol Environ Health A (2007) 0.85
Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice. Regul Toxicol Pharmacol (2006) 0.84
Multi-dose-route, multi-species pharmacokinetic models for manganese and their use in risk assessment. J Toxicol Environ Health A (2010) 0.84
Derivation of an inhalation reference concentration based upon olfactory neuronal loss in male rats following subchronic acetaldehyde inhalation. Inhal Toxicol (2008) 0.84
Evaluation of placental and lactational pharmacokinetics of PFOA and PFOS in the pregnant, lactating, fetal and neonatal rat using a physiologically based pharmacokinetic model. Reprod Toxicol (2011) 0.84
A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution. J Pharm Pharmacol (2012) 0.84
Physiologically based pharmacokinetic (PBPK) modeling of interstrain variability in trichloroethylene metabolism in the mouse. Environ Health Perspect (2014) 0.84
Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations. Regul Toxicol Pharmacol (2006) 0.83
Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition. J Toxicol Environ Health A (2008) 0.83
Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul Toxicol Pharmacol (2002) 0.83
Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. J Pharm Sci (2013) 0.83
In vitro metabolism of di(2-ethylhexyl) phthalate (DEHP) by various tissues and cytochrome P450s of human and rat. Toxicol In Vitro (2011) 0.83
Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorption. J Pharm Sci (2012) 0.83
Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. Inhal Toxicol (2003) 0.82
Molecular signaling network motifs provide a mechanistic basis for cellular threshold responses. Environ Health Perspect (2014) 0.82
Evaluation and prediction of pharmacokinetics of PFOA and PFOS in the monkey and human using a PBPK model. Regul Toxicol Pharmacol (2011) 0.82
Evaluation of gene expression changes in human primary uroepithelial cells following 24-hr exposures to inorganic arsenic and its methylated metabolites. Environ Mol Mutagen (2012) 0.81
Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform. Risk Anal (2007) 0.81
In vitro intestinal and hepatic metabolism of Di(2-ethylhexyl) phthalate (DEHP) in human and rat. Toxicol In Vitro (2013) 0.81
Pharmacokinetic modeling of manganese. I. Dose dependencies of uptake and elimination. J Toxicol Environ Health A (2007) 0.81
Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin. J Pharm Sci (2013) 0.81
Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model. Reprod Toxicol (2011) 0.81
An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. Toxicol Sci (2002) 0.81
A pharmacokinetic model of the intracellular dosimetry of inhaled nickel. J Toxicol Environ Health A (2007) 0.80
How can biologically-based modeling of arsenic kinetics and dynamics inform the risk assessment process? - A workshop review. Toxicol Appl Pharmacol (2008) 0.80
Lactational transfer of manganese in rats: predicting manganese tissue concentration in the dam and pups from inhalation exposure with a pharmacokinetic model. Toxicol Sci (2009) 0.80
Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene. Risk Anal (2007) 0.80
Pharmacokinetic modeling of manganese. II. Hepatic processing after ingestion and inhalation. J Toxicol Environ Health A (2007) 0.80
Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMT-Part II: Physiologically Based Pharmacokinetic Modeling and Manganese Risk Assessment. J Toxicol (2012) 0.80
Pharmacokinetic modeling of manganese. III. Physiological approaches accounting for background and tracer kinetics. J Toxicol Environ Health A (2007) 0.79
Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model. AAPS J (2014) 0.79
Physiologically based pharmacokinetic modeling of styrene and styrene oxide respiratory-tract dosimetry in rodents and humans. Inhal Toxicol (2002) 0.79
Physiologically based pharmacokinetic/toxicokinetic modeling. Methods Mol Biol (2012) 0.78
Effects of endogenous formaldehyde in nasal tissues on inhaled formaldehyde dosimetry predictions in the rat, monkey, and human nasal passages. Toxicol Sci (2014) 0.78
Manganese tissue dosimetry in rats and monkeys: accounting for dietary and inhaled Mn with physiologically based pharmacokinetic modeling. Toxicol Sci (2008) 0.77
Comment on M.V. Evans and J.C. Caldwell: evaluation of two different metabolic hypotheses for dichloromethane toxicity using physiologically based pharmacokinetic modeling of in vivo gas uptake data exposure in female B6C3F1 mice, Toxicol. Appl. Pharmacol., 244, 280-290, 2010. Toxicol Appl Pharmacol (2010) 0.77
Development of 3D dynamic flow model of human liver and its application to prediction of metabolic clearance of 7-ethoxycoumarin. Tissue Eng Part C Methods (2014) 0.77
A hybrid CFD-PBPK model for naphthalene in rat and human with IVIVE for nasal tissue metabolism and cross-species dosimetry. Inhal Toxicol (2014) 0.77
Application of a physiologically based pharmacokinetic model for reference dose and reference concentration estimation for acetone. J Toxicol Environ Health A (2003) 0.77
Measurement of tumor-associated mutations in the nasal mucosa of rats exposed to varying doses of formaldehyde. Regul Toxicol Pharmacol (2010) 0.77